Use of alirocumab to reduce the risk of a major adverse cardiovascular event Effects of empagliflozin on hyperuricaemia and heart failureEmpagliflozin, a sodium-glucose cotransporter-2 inhibitor, induces a rapid and sustained reduction in serum uric acid levels and decreases the risk of cardiovascular death or hospitalization for heart failure. Camzyos approved to treat hypertrophic obstructive cardiomyopathy Health Canada approves use in patients with common form of heart disease. QUIZ: Cardiovascular disease in primary care Test your knowledge of Canada’s harmonized prevention and treatment guideline. One-stop shop: New Canadian cardiovascular disease guideline pulls together dozens of recommendations The guideline is an update to a 2018 iteration and adds 48 fresh recommendations. QUIZ: Fighting hypertension with food It’s been a quarter century since the publication of the first clinical trial of the Dietary Approaches to Stop Hypertension (DASH) diet. Low-carb vegan diet as effective as vegetarian approach for weight loss, glycemic control Vegetable oils and plant proteins beneficial for both type 2 diabetes and the planet. Will angiotensin receptor II blockers play a role in epilepsy prevention? Study examines whether ARB therapy is associated with a decreased incidence of new onset epilepsy in patients with hypertension. How income influences diabetes management Study shows income disparity linked to increased re-hospitalization rates. Hypertension linked to cognitive decline Taking hypertension medication slows the pace of decline, researchers say. First Previous 14 15 16 17 18 Next Last
